Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of rapcabtagene autoleucel in adult patients with CLL/SLL, DLBCL, ALL, and first-line high-risk large B-cell lymphoma
jRCT2013210066Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2022
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
01
Overview
Phase 2, open-label trial of rapcabtagene autoleucel and ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL) (4 arms), sponsored by Novartis. Primary endpoints: Dose recommendation, Safety and 3 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
rapcabtagene autoleucelibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)diffuse large B-cell lymphoma (DLBCL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2013210066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2013210066.